AYTU Aytu Biopharma Inc
Price (delayed)
$1.25
Market cap
$7.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.97
Enterprise value
$3.17M
Highlights
AYTU's EPS has soared by 75% YoY and by 15% QoQ
The company's net income has surged by 71% YoY and by 16% QoQ
Aytu Biopharma's equity has decreased by 6% YoY but it has increased by 3.1% QoQ
Aytu Biopharma's gross margin has decreased by 4.3% from the previous quarter but it has increased by 2.9% YoY
AYTU's revenue is down by 24% YoY and by 3.5% QoQ
The gross profit has contracted by 21% YoY and by 8% from the previous quarter
Key stats
What are the main financial stats of AYTU
Market
Valuations
Earnings
Shares outstanding
6.17M
Market cap
$7.71M
Enterprise value
$3.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.25
Price to sales (P/S)
0.11
EV/EBIT
1.18
EV/EBITDA
0.34
EV/Sales
0.05
Revenue
$68.76M
Gross profit
$46.37M
Operating income
-$8.74M
Net income
-$5.24M
EBIT
$2.69M
EBITDA
$9.31M
Free cash flow
$1.2M
Per share
Balance sheet
Liquidity
EPS
-$0.97
EPS diluted
-$1.75
Free cash flow per share
$0.2
Book value per share
$5
Revenue per share
$11.21
TBVPS
$10.81
Total assets
$116.23M
Total liabilities
$85.46M
Debt
$15.85M
Equity
$30.77M
Working capital
-$995,000
Debt to equity
0.52
Current ratio
0.98
Quick ratio
0.72
Net debt/EBITDA
-0.49
Margins
Efficiency
Dividend
EBITDA margin
13.5%
Gross margin
67.4%
Net margin
-7.6%
Operating margin
-12.7%
Return on assets
-4.4%
Return on equity
-17.6%
Return on invested capital
N/A
Return on capital employed
5.1%
Return on sales
3.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AYTU stock price
How has the Aytu Biopharma stock price performed over time
Intraday
-2.34%
1 week
-3.1%
1 month
-19.35%
1 year
-59.42%
YTD
-26.47%
QTD
-26.47%
Financial performance
How have Aytu Biopharma's revenue and profit performed over time
Revenue
$68.76M
Gross profit
$46.37M
Operating income
-$8.74M
Net income
-$5.24M
Gross margin
67.4%
Net margin
-7.6%
Aytu Biopharma's operating margin has shrunk by 131% QoQ and by 57% YoY
Aytu Biopharma's operating income has plunged by 124% from the previous quarter and by 20% YoY
The company's net income has surged by 71% YoY and by 16% QoQ
The company's net margin has surged by 62% YoY and by 14% QoQ
Growth
What is Aytu Biopharma's growth rate over time
Valuation
What is Aytu Biopharma stock price valuation
P/E
N/A
P/B
0.25
P/S
0.11
EV/EBIT
1.18
EV/EBITDA
0.34
EV/Sales
0.05
AYTU's EPS has soared by 75% YoY and by 15% QoQ
The P/B is 58% below the 5-year quarterly average of 0.6 and 50% below the last 4 quarters average of 0.5
Aytu Biopharma's equity has decreased by 6% YoY but it has increased by 3.1% QoQ
AYTU's P/S is 88% below its 5-year quarterly average of 0.9 and 45% below its last 4 quarters average of 0.2
AYTU's revenue is down by 24% YoY and by 3.5% QoQ
Efficiency
How efficient is Aytu Biopharma business performance
AYTU's ROS has soared by 136% YoY but it is down by 4.9% QoQ
The ROA has soared by 66% YoY and by 14% from the previous quarter
The ROE has soared by 64% YoY and by 15% from the previous quarter
Dividends
What is AYTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AYTU.
Financial health
How did Aytu Biopharma financials performed over time
Aytu Biopharma's total assets is 36% higher than its total liabilities
Aytu Biopharma's total liabilities has decreased by 13% YoY
AYTU's current ratio is down by 12% YoY
The company's debt is 48% lower than its equity
The debt to equity has contracted by 7% from the previous quarter but it has grown by 6% YoY
Aytu Biopharma's equity has decreased by 6% YoY but it has increased by 3.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.